TGA
The Prescription Medicines in Pregnancy database has now been updated to include the following new entries:
| Medicine | Pregnancy Category |
|---|---|
| abaloparatide | B3 |
| abrocitinib | D |
| atogepant | B3 |
| ceftazidime / avibactam | B3 |
| belumosudil | D |
| calcifediol | B3 |
| cipaglucosidase alfa / miglustat | D |
| crizanlizumab | B1 |
| danicopan | B3 |
| datopotamab deruxtecan | D |
| deutetrabenazine | B3 |
| doravirine | B1 |
| efgartigimod alfa | C |
| elafibranor | D |
| etranacogene dezaparvovec | B2 |
| fedratinib | D |
| fenfluramine | D |
| foslevodopa / foscarbidopa | B3 |
| fruquintinib | D |
| futibatinib | D |
| gilteritinib | D |
| inavolisib | D |
| inebilizumab | C |
| insulin icodec | B3 |
| lazertinib | D |
| leniolisib | D |
| letibotulinumtoxinA | B3 |
| linaclotide | B3 |
| linzagolix | D |
| lumasiran | B1 |
| luspatercept | D |
| marstacimab | D |
| mavacamten | D |
| nemolizumab | B1 |
| odevixibat | D |
| palopegteriparatide | B3 |
| pegunigalsidase alfa | B3 |
| respiratory syncytial virus (RSV) F protein mRNA | B1 |
| ritlecitinib | D |
| rozanolixizumab | D |
| sipavibart | B2 |
| sodium iodide [131I] | X |
| sotatercept | D |
| spesolimab | B1 |
| talazoparib | D |
| talquetamab | C |
| tebentafusp | C |
| teprotumumab | X |
| tezepelumab | B1 |
| tirbanibulin | D |
| toripalimab | D |
| tremelimumab | D |
| triamcinolone acetonide (ocular) | B3 |
| turoctocog alfa | B2 |
| ublituximab | C |
| velmanase alfa | D |
| vonicog alfa | B2 |
| vutrisiran | D |
| zilucoplan | D |
| apadamtase alfa / cinaxadamtase alfa | B1 |
| seladelpar | B1 |
The following database entries have been amended:
| Medicine | Safety Statement | Classification 1 | Classification 2 | Classification 3 |
|---|---|---|---|---|
| anacaulase-bcdb | From "Dermatology" to "Drugs Used in Dermatology" | From "Topical debridement drug" to "Topical" | Removed "Proteolytic enzyme enriched in bromelain" | |
| belantamab mafodotin | From "Based on the mechanism of action of the cytotoxic component monomethyl auristatin F, belantamab mafodotin can cause embryo-fetal harm when administered to a pregnant woman. The cytotoxic component kills rapidly dividing cells, which would affect a developing embryo. There is also a potential risk of heritable changes via aneuploidy in female germ cells" to "Based on its mechanism of action, belantamab mafodotin may cause embryofetal harm (embryotoxicity and teratogenicity) when administered to a pregnant woman" | |||
| vanzacaftor / tezacaftor / deutivacaftor | From "Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators" to "Inhalational agents" | |||
| From "delgocitinib" to "delgocitinib (dermal)" | From "Immunomodulating" to "Allergy and Immune System" | From "Topical kinase inhibitor for chronic hand eczema" to "Immunomodifiers" | ||
| baricitinib | From "Musculoskeletal System" to "Allergy and Immune System" | From "Antirheumatoid agents" to "Immunomodifiers" |
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
